European digital health company launches new initiative to help cardiology researchers create more clinical evidence
SAN DIEGO (PRWEB)
September 10, 2022
Over the past decade, digital health technologies have proliferated in clinical and non-clinical settings. The global digital health market size is expected to reach USD 430.52 billion by 20281. This industry growth has been driven by the continued expansion of digital connectivity, falling cost of sensors and other technological components, and an increase in patient engagement. Despite this growth, digital health players lack a comprehensive understanding of the clinical robustness and claims of digital health products and services. A lack of transparency and clinical validation prevents the digital health ecosystem from truly understanding the safety and effectiveness of digital health therapies. Therefore, it is critical that digital health players invest in clinical validation studies that generate high-quality evidence to inform product development and widespread clinical adoption.
As a result, Happitech announced the launch of its FastStart Research app. The Amsterdam-based digital health company designed the app to support researchers and advance the adoption of digital health technology in cardiac practice. The mobile research app uses photoplethysmography (PPG) technology to measure heart rate, heart rate variability, and atrial fibrillation. PPG is a non-invasive optical technique that uses light to detect blood volume changes in the microvasculature. The app can be used with any smartphone that has a camera and flash, making it widely accessible to researchers around the world.
The company offers the app for free to cardiology researchers and can customize features to meet a variety of requirements – getting a project from idea to launch in 2-4 weeks. The app makes it easy to collect data from large numbers of participants that can be downloaded and exported for analysis, giving researchers quick and easy access to the data they need.
We have several research partners, including Mount Sinai, Boston Children’s Hospital, OLVG, Vrije Universiteit Amsterdam, Hartstichting and UMC Utrecht. The technology is also highlighted by the Dutch Heart Association and recommended in the Dutch Cardiology Association screening guidelines.
Dr. David Putrino, PT, PhD – Director of Rehabilitation Innovation, Mount Sinai Health System spoke about working with Happitech: “The team understood our requirements and were able to customize the functionality of the research app to suit our specific needs. It was quick and easy to get started.”
The company hopes that by providing this technology to researchers, it will help remove some of the barriers associated with launching cardiac research initiatives. It is only through such efforts that the digital health industry can live up to its potential as a transformative force in healthcare.
“Happitech is committed to providing researchers with the tools they need to conduct important research. The FastStart Research app is just one example of how we are working to support the cardiac research community,” said Yosef Safi Harb, Founder and CEO of Happitech. “We hope that by partnering with researchers, we can help advance the field of cardiac care and improve patient outcomes around the world. »
Happitech’s PPG technology is CE certified and TGA approved to collect heart rate, heart rate variability, and atrial fibrillation measurements, all through the flashlight and camera lens of a modern smartphone. We have several research partners, including OLVG, Mount Sinai, Boston Children’s Hospital, Vrije Universiteit Amsterdam, Hartstichting and UMC Utrecht. The technology is also highlighted by the Dutch Heart Association and recommended in the Dutch Cardiology Association screening guidelines.
Share the article on social networks or by e-mail: